| Objective: | US peri-approval safety surveillance study |
| Number of Patients: | 2,585 |
| Number of Sites: | 50 |
| Lesion Type: | |
| Stent Platform: | TAXUS® Express2™ Paclitaxel-Eluting Stent |
| Release Kinetics: | Slow |
| Primary Endpoint: | 1-year site reported cardiac events |
| P.I. and Co-P.I.: | D. Cox, MD and J. Lasala, MD, PhD |
| Status: | Enrollment complete |
*The Directions for Use require proper preparation of the vessel prior to stent placement. This includes predilatation of the lesion/vessel with an appropriate diameter balloon. The safety and effectiveness of the TAXUS Express2 Stent have not been proven with direct stenting, SVG, AMI, bifurcations or ISR.
